Hovione reports that the US Food and Drug Administration (FDA) performed a pre-approval inspection to its plant in Loures, Portugal, covering two new drug application filings. At the conclusion of the inspection, the FDA issued a Form 483 with three inspectional observations.

The inspection carried out by the FDA lasted five days as initially planned, starting on December 1, 2014 and concluded on December 5, 2014. The inspection confirmed the site to be compliant with the principles and guidelines of good manufacturing practices (GMP).

On the outcome of the inspection, Luisa Paulo, Hovione’s compliance director, said in a company release: “Addressing these observations is the top priority of the site management and the points raised will be replied to within 15 working days from the receipt of the Form 483. We are taking this result to improve our quality system both here and at our other sites. The investigators spoke positively of many of our initiatives. We have a strong pipeline of products under development with new NDAs being filed in the next 12 months, and we need to work diligently to continue to deserve our clients' trust.”

Source: Hovione